Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 06 04:00PM ET
100.10
Dollar change
+1.75
Percentage change
1.78
%
IndexRUT P/E- EPS (ttm)-6.54 Insider Own18.44% Shs Outstand48.44M Perf Week1.91%
Market Cap4.94B Forward P/E- EPS next Y-1.52 Insider Trans-0.65% Shs Float39.53M Perf Month10.04%
Income-310.95M PEG- EPS next Q-0.96 Inst Own79.07% Short Float19.45% Perf Quarter6.39%
Sales338.46M P/S14.59 EPS this Y-3.05% Inst Trans-5.57% Short Ratio16.29 Perf Half Y35.45%
Book/sh1.92 P/B52.19 EPS next Y71.95% ROA-53.51% Short Interest7.69M Perf Year44.34%
Cash/sh6.64 P/C15.08 EPS next 5Y- ROE-171.61% 52W Range64.11 - 105.00 Perf YTD25.77%
Dividend Est.- P/FCF- EPS past 5Y-35.53% ROI-110.15% 52W High-4.67% Beta1.01
Dividend TTM- Quick Ratio2.37 Sales past 5Y88.16% Gross Margin88.88% 52W Low56.14% ATR (14)3.42
Dividend Ex-Date- Current Ratio2.44 EPS Y/Y TTM-44.44% Oper. Margin-72.64% RSI (14)60.26 Volatility3.13% 3.97%
Employees545 Debt/Eq2.07 Sales Y/Y TTM51.47% Profit Margin-91.87% Recom1.06 Target Price131.44
Option/ShortYes / Yes LT Debt/Eq2.04 EPS Q/Q-1.66% Payout- Rel Volume0.73 Prev Close98.35
Sales Surprise5.45% EPS Surprise3.14% Sales Q/Q81.27% EarningsNov 12 BMO Avg Volume471.93K Price100.10
SMA203.29% SMA508.53% SMA20020.56% Trades Volume346,631 Change1.78%
Date Action Analyst Rating Change Price Target Change
Sep-03-24Initiated Wells Fargo Overweight $140
Aug-06-24Upgrade BofA Securities Neutral → Buy $95 → $106
Jul-22-24Initiated Needham Buy $130
Apr-29-24Upgrade Morgan Stanley Equal-Weight → Overweight $90 → $115
Mar-19-24Initiated Robert W. Baird Outperform $108
Feb-06-24Initiated UBS Buy $111
Jan-25-24Initiated RBC Capital Mkts Outperform $126
Dec-13-23Initiated Citigroup Buy $125
Aug-08-23Upgrade BofA Securities Underperform → Neutral $59 → $81
Jan-05-23Initiated Piper Sandler Neutral $75
Nov-27-24 01:23PM
Nov-26-24 07:00AM
Nov-13-24 03:27AM
Nov-12-24 03:15PM
12:42PM
07:00AM Loading…
07:00AM
Nov-08-24 07:00AM
Nov-05-24 10:00AM
Oct-29-24 07:00AM
Oct-19-24 07:30AM
Oct-15-24 07:00AM
Sep-29-24 07:32AM
Sep-24-24 07:00AM
Sep-04-24 07:00AM
Aug-27-24 07:00AM
07:00AM Loading…
Aug-21-24 07:00AM
Aug-16-24 05:43AM
Aug-05-24 01:45PM
12:15PM
11:30AM
07:00AM
Jul-25-24 08:30AM
Jul-23-24 02:57PM
Jul-22-24 03:06PM
Jul-15-24 07:15AM
Jul-11-24 07:00AM
Jul-05-24 02:14PM
Jul-04-24 10:01AM
Jun-11-24 12:35PM
Jun-05-24 11:30AM
07:35AM Loading…
07:35AM
Jun-04-24 07:00AM
Jun-03-24 07:00AM
May-30-24 07:00AM
May-29-24 07:00AM
May-28-24 07:00AM
May-18-24 06:47AM
May-13-24 07:57PM
May-11-24 10:00AM
09:00AM
May-08-24 07:00AM
May-07-24 11:26AM
11:17AM
03:01AM
May-06-24 10:55PM
01:00PM
12:53PM
07:00AM
May-03-24 08:30AM
May-01-24 07:00AM
Apr-30-24 03:20PM
Apr-29-24 04:01PM
10:00AM
Apr-22-24 09:16AM
Apr-15-24 07:00AM
Apr-10-24 07:00AM
Apr-02-24 10:24AM
12:17AM
Apr-01-24 07:00AM
Mar-27-24 07:44AM
Mar-26-24 11:24AM
06:24AM
04:56AM
Mar-25-24 07:00AM
06:30AM
Mar-23-24 06:45AM
Mar-22-24 10:00AM
Mar-21-24 11:30AM
Mar-20-24 12:12PM
Mar-19-24 07:00AM
Mar-13-24 03:32PM
Mar-05-24 07:00AM
Feb-27-24 07:00AM
Feb-26-24 03:04PM
08:50AM
Feb-21-24 10:39AM
09:23AM
Feb-20-24 10:39PM
08:15AM
07:31AM
07:00AM
Feb-13-24 10:00AM
Feb-08-24 07:45AM
Jan-23-24 11:01AM
07:00AM
Jan-05-24 10:21AM
Jan-04-24 07:00AM
Jan-03-24 05:20AM
Jan-02-24 08:45AM
Jan-01-24 06:50AM
Dec-11-23 07:00AM
Dec-10-23 06:56AM
Dec-07-23 07:00AM
Nov-28-23 06:51PM
Nov-27-23 09:50AM
Nov-22-23 07:00AM
05:30AM
Nov-21-23 07:00AM
Nov-11-23 06:50AM
Nov-09-23 10:23AM
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Coleman MarkDirectorNov 19 '24Option Exercise5.9433,410198,45548,010Nov 20 04:30 PM
Saad Mark EDirectorSep 11 '24Option Exercise3.6711,01640,42921,018Sep 11 07:00 PM
Saad Mark EDirectorSep 11 '24Sale91.3111,0161,005,87110,002Sep 11 07:00 PM
Saad Mark EDirectorSep 11 '24Proposed Sale91.3111,0161,005,843Sep 11 04:32 PM
Jacobson Mark L.Chief Operating OfficerAug 09 '24Option Exercise4.0447,739192,86653,522Aug 09 07:27 PM
Jacobson Mark L.Chief Operating OfficerAug 09 '24Sale84.2647,7394,022,4885,783Aug 09 07:27 PM
Jacobson Mark L.OfficerAug 09 '24Proposed Sale84.2647,7394,022,490Aug 09 05:07 PM
Jacobson Mark L.Chief Operating OfficerMay 29 '24Option Exercise1.3013,69317,80113,693May 29 08:12 PM
Jacobson Mark L.Chief Operating OfficerMay 29 '24Sale74.317,910587,8135,783May 29 08:12 PM
Coleman MarkDirectorMay 28 '24Sale75.215,249394,77519,848May 29 08:11 PM
Coleman MarkDirectorMay 29 '24Sale75.145,248394,33314,600May 29 08:11 PM
Jacobson Mark L.Chief Operating OfficerApr 01 '24Option Exercise1.3024,66232,06124,662Apr 01 06:46 PM
Jacobson Mark L.Chief Operating OfficerApr 01 '24Sale77.2424,6621,904,9420Apr 01 06:46 PM
JEFFS ROGERDirectorMar 14 '24Option Exercise24.0129,976719,787137,732Mar 15 08:05 PM
JEFFS ROGERDirectorMar 15 '24Option Exercise29.912,34770,199123,103Mar 15 08:05 PM
JEFFS ROGERDirectorMar 14 '24Sale69.7029,9762,089,387120,756Mar 15 08:05 PM
JEFFS ROGERDirectorMar 15 '24Sale71.612,347168,062120,756Mar 15 08:05 PM